What Is Epidermal Growth Factor (EGF)? Structure, Receptor and Evidence
Growth factors
Epidermal growth factor (EGF) is a 53-amino-acid protein that tells cells to divide, move and survive by switching on a receptor called EGFR. Its discovery earned a Nobel Prize, it is one of the best-studied signalling molecules in biology, and it is also a source of confusion because the research on it is often mixed up with cosmetic marketing. This guide separates the biology from the claims.
What is epidermal growth factor?
Epidermal growth factor is a small, tightly folded protein. The mature human form is 53 amino acids long and is held in shape by three disulfide bonds, which are covalent bridges between pairs of cysteine residues (see our explainer on disulfide bonds in peptides). According to the UniProt record for human EGF (P01133), the mature chain is cut from a much larger 1,207-residue precursor called pro-EGF, a membrane-anchored protein that is expressed in tissues including the kidney and salivary gland.
The 53-residue chain is also known as urogastrone, a name from its early isolation from urine. Because it is a folded, disulfide-stabilised protein of roughly 6 kDa rather than a short linear sequence, EGF sits at the larger end of the “peptide” range and behaves more like a small protein for questions of stability and handling.
A short history: from mouse salivary glands to a Nobel Prize
EGF was identified by Stanley Cohen while working alongside Rita Levi-Montalcini, who had discovered nerve growth factor. The two shared the 1986 Nobel Prize in Physiology or Medicine “for their discoveries of growth factors”, according to the Nobel Prize organisation. The work established a new idea: that cells are told when to grow by soluble protein signals that bind to specific receptors on the cell surface. A 1990 review by Carpenter and Cohen in the Journal of Biological Chemistry remains a standard summary of that early work.
How EGF is studied to work
EGF acts through the epidermal growth factor receptor (EGFR, also called ErbB1), a receptor tyrosine kinase. When EGF binds the outer part of the receptor, two receptors pair up (dimerise), and the intracellular kinase domains phosphorylate each other. That creates docking sites for adaptor proteins and starts several signalling cascades, most famously the RAS–RAF–MEK–ERK (MAPK) pathway and the PI3K–AKT pathway. In cultured cells these routes are linked to proliferation, migration, differentiation and survival, which is why EGFR biology is so central to both wound-healing and cancer research (Herbst, 2004).
UniProt also lists a hormone-like role for EGF in the kidney: through EGFR and the ion channel TRPM6 it promotes renal magnesium reabsorption. It is a reminder that EGF is a normal physiological signal, not just a “growth” molecule.
Reported effects in the research literature
Because EGF stimulates growth of epithelial cells and some fibroblasts in the lab, researchers have asked whether supplying it to chronic wounds could help closure. The most developed line of work is the diabetic foot ulcer (DFU). A MEDICC review by Berlanga and colleagues describes Heberprot-P, a Cuban product containing recombinant human EGF that is injected around and into the ulcer, and summarises the rationale: tissue from people with diabetes may contain less EGF, and delivering it into the wound bed may help granulation and closure.
What the human evidence shows
The trial evidence is more cautious than the biology suggests. A Cochrane review (Martí-Carvajal and colleagues, 2015) pooled 28 randomised trials with 2,365 participants testing 11 different growth-factor products for diabetic foot ulcers. The authors judged all of the trials underpowered and at high risk of bias, and the main finding, that growth factors as a group increased complete healing (risk ratio 1.51), was rated low-quality evidence. Half of the trials were industry-sponsored.
A 2023 meta-analysis in F1000Research looked specifically at EGF against placebo. It pooled 8 randomised trials with 620 participants (337 EGF, 283 placebo). The pooled risk ratio for healing was 3.04 at 4 weeks (95% CI 0.50–18.44), 2.59 at 8 weeks (1.42–4.72) and 1.01 at 12 weeks (0.42–2.46). Only the 8-week result excludes “no difference”, and heterogeneity between trials was moderate to high (I² 49–77%).
Put simply: there are signals worth studying, but the evidence is mixed and limited rather than conclusive. We did not find high-quality trial evidence to cite for cosmetic or “anti-ageing” uses of EGF, so claims in that area should be read as marketing until backed by independent, controlled data.
Handling and storage in a research context
As a disulfide-stabilised protein, EGF is typically supplied for laboratory work as a lyophilised (freeze-dried) powder and handled with the same sterile-technique and concentration-math principles as other research proteins. Our reconstitution calculator and concentration converter cover the arithmetic, and the reconstitution guide and sterile technique guide cover practice. Always follow the manufacturer’s data sheet for a specific product. Biological units (IU) are not mass units; see peptides versus small molecules for why concentration and activity need care.
Cautions and considerations
EGFR signalling is deeply connected to cell proliferation, and over-activity of the pathway is a recognised feature of several cancers. That is the main reason EGF is studied carefully and why no source we cite supports casual use. EGF is also not an “approved” general-purpose treatment: the DFU work concerns a specific, injected recombinant product evaluated in clinical trials.
Frequently asked questions
Is epidermal growth factor a peptide or a protein?
At 53 amino acids with three disulfide bonds it sits on the boundary. Many sources call it a polypeptide; its folded structure makes it behave like a small protein.
What does EGF do in the body?
It binds EGFR on cell surfaces and activates signalling that promotes growth, migration and survival of epithelial cells and some fibroblasts. UniProt also lists a role in renal magnesium handling.
Does EGF heal diabetic foot ulcers?
Trials of injected recombinant EGF have shown some signals, but a 2023 meta-analysis found a significant effect only at 8 weeks, with substantial heterogeneity, and the broader Cochrane evidence on growth factors is low quality.
Why is EGFR important in cancer research?
The receptor’s growth-promoting signalling can be overactive in some tumours, so EGFR has become a major drug target. That is also why uncontrolled EGF exposure is treated cautiously.
References
- UniProt P01133 — Pro-epidermal growth factor (EGF), human
- The Nobel Prize in Physiology or Medicine 1986 — Stanley Cohen and Rita Levi-Montalcini
- Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 1990 (PMID 2186024)
- Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004 (PMID 15142631)
- Berlanga J et al. Heberprot-P: a novel product for treating advanced diabetic foot ulcer. MEDICC Rev 2013 (PMID 23396236)
- Martí-Carvajal AJ et al. Growth factors for treating diabetic foot ulcers. Cochrane Database Syst Rev 2015 (PMID 26509249)
- Epidermal growth factor outperforms placebo in the treatment of diabetic foot ulcer: a meta-analysis. F1000Research 2023 (PMID 37867626)
Informational only — not medical advice. This article is for educational purposes. It does not recommend, sell or instruct personal human use of any compound. Consult a qualified healthcare professional for any health decision. Content is intended for adults 21+. Verify scientific details against the primary sources cited.